Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Expanded Access for LJPC-501

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03245528
Expanded Access Status : Approved for marketing
First Posted : August 10, 2017
Last Update Posted : March 8, 2018
Information provided by (Responsible Party):
La Jolla Pharmaceutical Company

Brief Summary:
The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Condition or disease Intervention/treatment
Catecholamine Resistant Hypotension (CRH) Distributive Shock High Output Shock Sepsis Vasodilatory Shock Drug: LJPC-501

Detailed Description:

Primary Objective

The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Secondary Objective

The secondary objective of the study is to assess the safety of LJPC-501.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Treatment IND/Protocol
Official Title: Expanded Access for LJPC-501

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: LJPC-501
    angiotensin II

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients must be adults ≥ 18 years of age who remain hypotensive despite fluid therapy and vasopressor therapy and who received or are receiving a total sum norepinephrine (NE) equivalent unit dose of > 0.2 µg/kg/min for at least 2 hours prior to LJPC-501 infusion.
  • Patients must have central venous access and an arterial line present, which is expected to remain for the duration of the LJPC-501 infusion.
  • Patients must be adequately volume resuscitated in the opinion of the treating investigator.
  • Patients must have clinical features of distributive shock documented by either estimated or measured CI > 2.3 L/min/m^2 determined by echocardiogram or another cardiac output monitoring modality OR a concurrent CVP > 8 mmHg and ScvO2 > 70%.
  • Patient or legal surrogate is willing and able to provide informed consent per local guidance and patient/legal surrogate is willing to comply with all protocol requirements.

Exclusion Criteria:

  • Patients with a MAP > 80 mmHg.
  • Patients diagnosed with acute occlusive coronary syndrome requiring intervention.
  • Patients who have been on ECMO < 6 hours.
  • Patients in liver failure with a MELD score ≥ 30.
  • Patients not mechanically ventilated with a history of asthma or who are currently experiencing bronchospasm requiring the use of inhaled bronchodilators.
  • Patients with acute mesenteric ischemic or history of mesenteric ischemia.
  • Patients with Raynaud's phenomenon, systemic sclerosis, or vasospastic disease.
  • Patients with an expected lifespan of < 24 hours.
  • Patients with active bleeding AND an anticipated need for transfusion of > 4 units PRBCs within 48 hours of the initiation of LJPC-501.
  • Patients with active bleeding AND hemoglobin < 7 g/dL.
  • Patients with an ANC < 500 cells/mm^3.
  • Patients with a known allergy to mannitol.
  • Patients who are currently participating in an investigational interventional trial.
  • Women who are known to be pregnant at the time of Screening or have a positive serum or urine β-hCG, if of childbearing potential.

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: La Jolla Pharmaceutical Company Identifier: NCT03245528    
Other Study ID Numbers: LJ501-EAP01
First Posted: August 10, 2017    Key Record Dates
Last Update Posted: March 8, 2018
Last Verified: March 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Vascular Diseases
Cardiovascular Diseases
Angiotensin II
Vasoconstrictor Agents